Pharmacokinetic evaluation of capecitabine in breast cancer
作者： Gennaro Daniele , Marianna Gallo , Maria Carmela Piccirillo , Pasqualina Giordano , Amelia D'Alessio
DOI: 10.1517/17425255.2013.759939
关键词: Drug 、 Breast cancer 、 Medicine 、 Pharmacology 、 Prodrug 、 Pharmacokinetics 、 Oncology 、 English language 、 Internal medicine 、 Pharmacodynamics 、 Capecitabine 、 Metastatic breast cancer
摘要: Introduction: Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is adsorbed in its intact form through the intestine and metabolized to 5-FU tumour cells. In metastatic breast cancer (MBC), capecitabine effective well-tolerated therapeutic option both monotherapy combination with chemotherapeutic or molecular-targeted agents. Areas covered: We summarized data on pharmacokinetics pharmacodynamics capecitabine. also produced a general review most relevant clinical studies MBC. A literature search was performed using PubMed database including selected articles published English language up October 2012. Expert opinion: The unique pharmacodynamic/pharmacokinetic features represent bases reduced toxicity activity several tumours. Although during past 10 years there has been increasing use this drug MBC as single agent combination, encouraging results well tolerated active...
elsevier.com
informahealthcare.com参考文章(69)
Anne-Michelle Noone, John L Marshall, Jun F Sun, Craig Norris, Margaret Amankwa-Sakyi, Rebekah R Wu, Rebecca Slack, Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointestinal cancer research : GCR. ,vol. 3, pp. 134- 140 ,(2009)
L C Pronk, P Vasey, A Sparreboom, B Reigner, A S Th Planting, R J Gordon, B Osterwalder, J Verweij, C Twelves, A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours British Journal of Cancer. ,vol. 83, pp. 22- 29 ,(2000) , 10.1054/BJOC.2000.1160
Ian R. Judson, Philip J. Beale, José M. Trigo, Wynne Aherne, Thomas Crompton, David Jones, Ernie Bush, Bruno Reigner, A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Investigational New Drugs. ,vol. 17, pp. 49- 56 ,(1999) , 10.1023/A:1006263400888
M Mackean, A Planting, C Twelves, J Schellens, D Allman, B Osterwalder, B Reigner, T Griffin, S Kaye, J Verweij, Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. Journal of Clinical Oncology. ,vol. 16, pp. 2977- 2985 ,(1998) , 10.1200/JCO.1998.16.9.2977
D R Budman, N J Meropol, B Reigner, P J Creaven, S M Lichtman, E Berghorn, J Behr, R J Gordon, B Osterwalder, T Griffin, Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. Journal of Clinical Oncology. ,vol. 16, pp. 1795- 1802 ,(1998) , 10.1200/JCO.1998.16.5.1795
Miguel A. Villalona-Calero, Geoffrey R. Weiss, Howard A. Burris, Maura Kraynak, Gladys Rodrigues, Ronald L. Drengler, S. Gail Eckhardt, Bruno Reigner, Judy Moczygemba, Hans Ulrich Burger, Tom Griffin, Daniel D. Von Hoff, Eric K. Rowinsky, Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies Journal of Clinical Oncology. ,vol. 17, pp. 1915- 1925 ,(1999) , 10.1200/JCO.1999.17.6.1915
M Utoh, E Weidekamm, L Banken, C Twelves, J Cassidy, B Reigner, B Roos, J Verweij, B Osterwalder, L Dirix, D Allman, Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clinical Cancer Research. ,vol. 4, pp. 941- 948 ,(1998)
P. Fumoleau, R. Largillier, C. Clippe, V. Dièras, H. Orfeuvre, T. Lesimple, S. Culine, B. Audhuy, D. Serin, H. Curé, E. Vuillemin, J.-F. Morère, F. Montestruc, Z. Mouri, M. Namer, Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. European Journal of Cancer. ,vol. 40, pp. 536- 542 ,(2004) , 10.1016/J.EJCA.2003.11.007
Devika Gajria, Kim Feigin, Lee K. Tan, Sujata Patil, Stephanie Geneus, Maria Theodoulou, Larry Norton, Clifford A. Hudis, Tiffany A. Traina, Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer Cancer. ,vol. 117, pp. 4125- 4131 ,(2011) , 10.1002/CNCR.25992
Gabriel N. Hortobagyi, Henry L. Gomez, Rubi K. Li, Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Guillermo L. Lerzo, Xavier B. Pivot, Fernando Hurtado de Mendoza, Binghe Xu, Linda T. Vahdat, Ronald A. Peck, Pralay Mukhopadhyay, Henri H. Roché, Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes Breast Cancer Research and Treatment. ,vol. 122, pp. 409- 418 ,(2010) , 10.1007/S10549-010-0901-4